On November 4, Tianjin Pharmaceutical Group Co., Ltd. issued an announcement stating that its subsidiary, Tianjin Pharmaceutical Peace Co., Ltd., received the "Approval Notice for Supplementary Application for Compound Potassium Hydrogen Phosphate Injection" issued by the National Medical Products Administration, approving the product to pass the consistency evaluation of generic drug quality and efficacy.

It is understood that compound potassium hydrogen phosphate injection, as a phosphorus supplement, is mainly used to correct hypophosphatemia in adult and pediatric patients when oral or enteral nutrition is not feasible, insufficient, or contraindicated; and for parenteral nutrition in adult and pediatric patients when oral or enteral nutrition is not feasible, insufficient, or contraindicated. Passing the consistency evaluation will enhance the market competitiveness of this drug and will have a positive impact on Tianjin Pharmaceutical Group's ability to fully leverage its integrated API and formulation advantages, expand its domestic formulation market, and improve the company's performance.

Articles: Board Office of Tianjin Pharmaceutical Group Co., Ltd., China Securities Journal (China Securities Network)